ADNI began in October 2004. The overall goal is to validate biomarkers for Alzheimer’s disease clinical trials. One aim is to find, validate and standardize more sensitive and accurate methods to detect Alzheimer’s disease at earlier stages and mark its progress through biomarkers. The study gathered and analyzed thousands of brain scans, genetic profiles, and biomarkers in blood and cerebrospinal fluid that are used to measure the progress of disease or the effects of treatment. More information on ADNI-info.org. All data is publically available at USC/LONI/ADNI.
The three overarching longitudinal ADNI study goals are:
- Validation of biomarkers, especially for amyloid and tau, for use in AD clinical trials.
- To detect Alzheimer’s disease (AD) at the earliest stage possible and identify ways to track the disease through biomarkers.
- To support advances in AD intervention, prevention and treatment through the application of new diagnostic methods to apply at the earliest stages technically possible – when intervention may be most effective.
- To continually develop ADNI’s now- legendary data access policy and continuously improve and expand the unprecedented data sharing model.
Last update – 07/02/2017